🇺🇸 FDA
Patent

US 12012384

Dextrorphan prodrugs and processes for making and using them

granted A61KA61K47/542A61P

Quick answer

US patent 12012384 (Dextrorphan prodrugs and processes for making and using them) held by Zevra Therapeutics, Inc. expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Zevra Therapeutics, Inc.
Grant date
Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K47/542, A61P, A61P11/14, A61P25/36